| Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors F Doz, CM Van Tilburg, B Geoerger, M Højgaard, I Øra, V Boni, M Capra, ... Neuro-oncology 24 (6), 997-1007, 2022 | 127 | 2022 |
| Elimination of ascorbic acid after high‐dose infusion in prostate cancer patients: a pharmacokinetic evaluation TK Nielsen, M Højgaard, JT Andersen, HE Poulsen, J Lykkesfeldt, ... Basic & clinical pharmacology & toxicology 116 (4), 343-348, 2015 | 85 | 2015 |
| Weekly ascorbic acid infusion in castration-resistant prostate cancer patients: A single-arm phase II trial TK Nielsen, M Højgaard, JT Andersen, NR Jørgensen, B Zerahn, ... Translational andrology and urology 6 (3), 517, 2017 | 67 | 2017 |
| Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results TA Yap, E Fontana, EK Lee, DR Spigel, M Højgaard, S Lheureux, ... Nature medicine 29 (6), 1400-1411, 2023 | 48 | 2023 |
| The plasma atrial natriuretic peptide response to arm and leg exercise in humans: effect of posture TW Vogelsang, CC Yoshiga, M Højgaard, A Kjaer, J Warberg, NH Secher, ... Experimental Physiology 91 (4), 765-771, 2006 | 40 | 2006 |
| ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling–a national, phase 2, prospective, multi-drug, non-randomized, open-label … T Kringelbach, M Højgaard, K Rohrberg, I Spanggaard, BE Laursen, ... BMC cancer 23 (1), 182, 2023 | 17 | 2023 |
| Modeling metastatic colonization in a decellularized organ scaffold‐based perfusion bioreactor M Rafaeva, ER Horton, ARD Jensen, CD Madsen, R Reuten, O Willacy, ... Advanced healthcare materials 11 (1), 2100684, 2022 | 16 | 2022 |
| Abstract CT030: Genomic and pathologic determinants of response to RP-3500, an ataxia telangiectasia and Rad3-related inhibitor (ATRi), in patients (pts) with DNA damage repair … TA Yap, IM Silverman, E Fontana, E Lee, D Spigel, M Højgaard, ... | 11 | 2022 |
| Incarcerated and perforated stomach found in parastomal hernia: a case of a stomach in a parastomal hernia and subsequent strangulation-induced necrosis and perforation AK Marsh, M Hoejgaard Journal of Surgical Case Reports 2013 (4), rjt029, 2013 | 11 | 2013 |
| Abstract PR008: MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid … TA Yap, A Schram, EK Lee, F Simpkins, MC Weiss, P LoRusso, ... Molecular Cancer Therapeutics 22 (12_Supplement), PR008-PR008, 2023 | 6 | 2023 |
| Seminoma in the testis presenting as hemospermia S Beji, M Hoejgaard, P Lyngdorf Case Reports in Nephrology and Dialysis 2 (2), 135-137, 2012 | 6 | 2012 |
| New pathogenic germline variants identified in mesothelioma L Belcaid, B Bertelsen, K Wadt, I Tuxen, I Spanggaard, M Højgaard, ... Lung Cancer 179, 107172, 2023 | 5 | 2023 |
| Abstract CT018: Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia-and Rad3-related kinase inhibitor (ATRi) camonsertib in patients … TA Yap, S Yadav, B Herzberg, BA Carneiro, E Fontana, M Højgaard, ... Cancer Research 83 (8_Supplement), CT018-CT018, 2023 | 4 | 2023 |
| Abstract CC04-01: first-in-human biomarker-driven phase I TRESR trial of ataxia telangiectasia and Rad3-related inhibitor (ATRi) RP-3500 in patients (pts) with advanced solid … T Yap, E Lee, D Spigel, E Fontana, M Højgaard, S Lheureux, NB Mettu, ... Molecular Cancer Therapeutics 20 (12_Supplement), CC04-01-CC04-01, 2021 | 4 | 2021 |
| Development of a practical nomogram for personalized anemia management in patients treated with ataxia telangiectasia and rad3-related inhibitor camonsertib E Rosen, TA Yap, EK Lee, M Højgaard, NB Mettu, S Lheureux, ... Clinical Cancer Research 30 (4), 687-694, 2024 | 3 | 2024 |
| 622 A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099318, in patients with select advanced solid tumors D Pinato, R Plummer, M Gutierrez, J Yachnin, A Schiza, M Hojgaard, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 3 | 2022 |
| Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor … E Rosen, IM Silverman, E Fontana, EK Lee, DR Spigel, M Højgaard, ... Journal of Clinical Oncology 40 (16_suppl), 3082-3082, 2022 | 3 | 2022 |
| 5MO Comprehensive dose-finding strategy for single-agent RP-3500, a highly selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase E Fontana, E Lee, E Rosen, D Spigel, M Højgaard, S Lheureux, NB Mettu, ... Annals of Oncology 33, S3-S4, 2022 | 3 | 2022 |
| Ureteral injuries during photoselective vaporization of the prostate M Hojgaard, KJ Mikines Scandinavian journal of urology and nephrology 44 (4), 265-268, 2010 | 3 | 2010 |
| Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study) E Fontana, E Rosen, EK Lee, M Højgaard, NB Mettu, S Lheureux, ... JNCI: Journal of the National Cancer Institute 116 (9), 1439-1449, 2024 | 2 | 2024 |
Stephanie LheureuxPrincess Margaret Cancer CentrePatvirtintas el. paštas uhn.ca